Samsung Pharm (KO:001360) — Market Cap & Net Worth
Market Cap & Net Worth: Samsung Pharm (001360)
Samsung Pharm (KO:001360) has a market capitalization of $88.28 Million (₩130.26 Billion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19734 globally and #1013 in its home market, demonstrating a 4.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Samsung Pharm's stock price ₩1384.00 by its total outstanding shares 94120296 (94.12 Million). Also see 001360 total asset value for a full breakdown of the balance sheet.
Samsung Pharm Market Cap History: 2015 to 2026
Samsung Pharm's market capitalization history from 2015 to 2026. Data shows change from $500.82 Million to $88.28 Million (-17.97% CAGR). Also see 001360 cash flow metrics for how efficiently the company converts equity into cash flow.
Samsung Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Samsung Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Samsung Pharm (001360) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Samsung Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $500.82 Million | $42.16 Billion | -$994.38 Million | 0.01x | N/A |
| 2016 | $244.17 Million | $48.22 Billion | -$21.62 Billion | 0.01x | N/A |
| 2017 | $234.54 Million | $41.92 Billion | -$7.54 Billion | 0.01x | N/A |
| 2018 | $161.37 Million | $46.48 Billion | -$2.08 Billion | 0.00x | N/A |
| 2019 | $267.57 Million | $44.57 Billion | $6.89 Billion | 0.01x | 0.04x |
| 2020 | $385.89 Million | $48.27 Billion | -$39.88 Billion | 0.01x | N/A |
| 2021 | $314.14 Million | $54.90 Billion | -$40.28 Billion | 0.01x | N/A |
| 2022 | $171.26 Million | $51.83 Billion | -$25.09 Billion | 0.00x | N/A |
| 2023 | $138.73 Million | $51.96 Billion | -$24.81 Billion | 0.00x | N/A |
| 2024 | $98.10 Million | $44.29 Billion | -$14.09 Billion | 0.00x | N/A |
Competitor Companies of 001360 by Market Capitalization
Companies near Samsung Pharm in the global market cap rankings as of September 17, 2026. Review Samsung Pharm tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Samsung Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Samsung Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Samsung Pharm's market cap moved from $500.82 Million to $ 88.28 Million, with a yearly change of -17.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩88.28 Million | -9.54% |
| 2025 | ₩97.59 Million | -0.52% |
| 2024 | ₩98.10 Million | -29.29% |
| 2023 | ₩138.73 Million | -18.99% |
| 2022 | ₩171.26 Million | -45.48% |
| 2021 | ₩314.14 Million | -18.60% |
| 2020 | ₩385.89 Million | +44.22% |
| 2019 | ₩267.57 Million | +65.81% |
| 2018 | ₩161.37 Million | -31.20% |
| 2017 | ₩234.54 Million | -3.94% |
| 2016 | ₩244.17 Million | -51.25% |
| 2015 | ₩500.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Samsung Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $88.28 Million USD |
| MoneyControl | $88.28 Million USD |
| MarketWatch | $88.28 Million USD |
| marketcap.company | $88.28 Million USD |
| Reuters | $88.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more